[1]王世鹏 付秋玉 刘剑雄 胡咏梅.非奈利酮临床应用研究进展[J].心血管病学进展,2025,(10):879.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.004]
　WANG Shipeng,FU Qiuyu,LIU Jianxiong,et al.Clinical Application of Finerenone[J].Advances in Cardiovascular Diseases,2025,(10):879.[doi:10.16806/j.cnki.issn.1004-3934.2025.10.004]
点击复制

非奈利酮临床应用研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年10期
页码:
879
栏目:
综述
出版日期:
2025-10-25

文章信息/Info

Title:
Clinical Application of Finerenone
作者:
王世鹏 付秋玉 刘剑雄 胡咏梅
(四川大学附属成都市第二人民医院心内科,四川 成都 610017)
Author(s):
WANG Shipeng; FU Qiuyu; LIU Jianxiong; HU Yongmei
(Department of Cardiology,The Second People’s Hospital of Chengdu Affiliated to Sichuan University,Chengdu 610017,Sichuan,China)
关键词:
非奈利酮; 非甾体类盐皮质激素受体拮抗剂; 心血管-肾脏-代谢综合征
Keywords:
Finerenone; Nonsteroidal corticosteroid receptor antagonist; Cardiovascular-kidney-metabolic syndrome
DOI:
10.16806/j.cnki.issn.1004-3934.2025.10.004
摘要:
盐皮质激素受体拮抗剂，螺内酯和依普利酮等，被强烈推荐用于治疗心力衰竭，但因高钾血症、肾功能障碍等不良反应，使得盐皮质激素受体拮抗剂的广泛使用受到限制。非奈利酮作为一种新型的非甾体盐皮质激素受体拮抗剂，在治疗心力衰竭和慢性肾脏病等方面具有更好的有效性和安全性。现对非奈利酮在治疗心血管和相关疾病中的应用进展进行综述。
Abstract:
Mineralocorticoid receptor antagonist，spirolactone and eplerenone are strongly recommended in the treatment of heart faliure,however ,due to hyperkalemia,renal dysfunction and other adverse reactions,the wide use of mineralocorticoid receptor antagonists is limited.Finerenone,as a new non-steroidal corticosteroid receptor antagonist,has better efficacy and safety in the treatment of heart failure and chronic kidney disease. This article reviews the application of finerenone in the treatment of cardiovascular and related diseases

参考文献/References:

[1] Aggarwal R,Ostrominski JW,Vaduganathan M. Prevalence of Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults,2011-2020[J]. JAMA,2024,331(21):1858-1860.

[2] Ostrominski JW,Arnold SV,Butler J,et al.Prevalence and overlap of cardiac,renal,and metabolic conditions in US adults,1999-2020[J]. JAMA Cardiol,2023,8(11):1050-1060.

[3] Ostrominski JW,Claggett BL,Miao ZM,et al. Cardiovascular-kidney-metabolic overlap in heart?failure with mildly reduced or preserved ejection fraction:a trial-level analysis[J]. J Am Coll Cardiol,2024,84(2):223-228.

[4] Pitt B,Anker SD,B?hm M,et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease[J]. Eur J Heart Fail,2015,17(2):224-232.

[5] Bakris GL,Agarwal R,Anker SD,et al; FIDELIO-DKD investigators,effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med,2020,383(23):2219-2229.

[6] Pitt B,Filippatos G,Agarwal R,et al; FIGARO-DKD investigators,cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med,2021,385(24):2252-2263.

[7] Droebner K,Pavkovic M,Grundmann M,et al. Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis[J]. Am J Nephrol,2021,52(7):588-601.

[8] Grune J,Beyhoff N,Smeir E,et al. Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone’s antifibrotic activity[J]. Hypertension,2018,71(4):599-608.

[9] Savarese G,Becher PM,Lund LH,et al. Global burden of heart failure: a comprehensive and updated review of epidemiology[J]. Cardiovasc Res,2023,118(17):3272-3287.

[10] Hao G,Wang X,Chen Z,et al.Prevalence of heart failure and left ventricular dysfunction in China: the China Hypertension Survey,2012-2015[J]. Eur J Heart Fail,2019,21(11):1329-1337.

[11] Solomon SD,McMurray JJV,Vaduganathan M,et al.Finerenone in heart failure with mildly reduced or preserved ejection fraction[J]. N Engl J Med,2024,391(16):1475-1485.

[12] Kolkhof P,Delbeck M,Kretschmer A,et al. Finerenone,a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury[J]. J Cardiovasc Pharmacol,2014,64(1):69-78.

[13] Kolkhof P,Jaisser F,Kim SY,et al. Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside[J]. Handb Exp Pharmacol,2017,243:271-305.

[14] Agarwal R,Kolkhof P,Bakris G,et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine[J]. Eur Heart J,2021,42(2):152-161.

[15] Kintscher U,Bakris GL,Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease[J]. Br J Pharmacol,2022,179(13):3220-3234.

[16] Ruilope LM,Agarwal R,Chan JC,et al. Rationale,design,and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy[J] Am J Nephrol ,2014,40(6):572-81.

[17] Katayama S,Yamada D,Nakayama M,et al. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy[J] J Diabetes Complications ,2017,31(4):758-765.

[18] Zhou J,Kang L,Gu C,et al. Effectiveness and safety of finerenone in diabetic kidney disease patients: a real-world observational study from China[J]. Ren Fail,2024,46(2):2400541.

[19] Bakris GL,Agarwal R,Anker SD,et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med,2020,383(23):2219-2229.

[20] Filippatos G,Anker SD,Agarwal R,et al. Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial[J]. Circulation,2022,145(6):437-447.

[21] Vaduganathan M,Filippatos G,Claggett BL,et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes:FINE-HEART pooled analysis of cardiovascular,kidney and mortality outcomes[J]. Nat Med,2024,30(12):3758-3764.

[22] Desai NR,Navaneethan SD,Nicholas SB,et al. Design and rationale of FINE-REAL:a prospective study of finerenone in clinical practice [J]. J Diabetes Complications,2023,37(4):108411.

[23] Zhou L,Li W. Effectiveness and safety of finerenone in Chinese CKD patients without diabetes:a retrospective,real-world study[J] Int Urol Nephrol ,2024,56(12):3877-3885.

[24] Heerspink HJL,Agarwal R,Bakris GL,et al. Design and baseline characteristics of the Finerenone,in addition to standard of care,on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial[J]. Nephrol Dial Transplant,2025,40(2):308-319.

相似文献/References:

[1]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
　GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]

更新日期/Last Update: 2026-01-15